Taylor et al. BMC Cancer 2010, 10:541 http://www.biomedcentral.com/1471-2407/10/541 hormone stimulation of prostate, the carcinogenesis study, and evaluation of morphological alterations in various prostate lobes; KC also evaluated the data and wrote the manuscript, which all authors have read and approved. Competing interests The authors declare that they have no competing interests. Received: 28 April 2010 Accepted: 8 October 2010 Published: 8 October 2010 References 1. Gill JK, Wilkens LR, Pollak MN, Stanczyk FZ, Kolonel LN: Androgens, growth factors, and risk of prostate cancer: the Multiethnic Cohort. Prostate 2010, 70(8):906-915. 2. Alberti C: Hereditary/familial versus sporadic prostate cancer: few indisputable genetic differences and many similar clinicopathological features. Eur Rev Med Pharmacol Sci 2010, 14(1):31-41. 3. Marlow NM, Halpern MT, Pavluck AL, Ward EM, Chen AY: Disparities associated with advanced prostate cancer stage at diagnosis. J Health Care Poor Underserved 2010, 21(1):112-131. 4. Yang RM, Naitoh J, Murphy M, Wang HJ, Phillipson J, deKernion JB, Loda M, Reiter RE: Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 1998, 159(3):941-945. 5. Roy S, Gu M, Ramasamy K, Singh RP, Agarwal C, Siriwardana S, Sclafani RA, Agarwal R: p21/Cip1 and p27/Kip1 Are essential molecular targets of inositol hexaphosphate for its antitumor efficacy against prostate cancer. Cancer Res 2009, 69(3):1166-1173. 6. Macri E, Loda M: Role of p27 in prostate carcinogenesis. Cancer Metastasis Rev 1998, 17(4):337-344. 7. Cordon-Cardo C, Koff A, Drobnjak M, Capodieci P, Osman I, Millard SS, Gaudin PB, Fazzari M, Zhang ZF, Massague J, et al: Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst 1998, 90(17):1284-1291. 8. Toyoshima H, Hunter T: p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994, 78(1):67-74. 9. Sgambato A, Cittadini A, Faraglia B, Weinstein IB: Multiple functions of p27 (Kip1) and its alterations in tumor cells: a review. J Cell Physiol 2000, 183(1):18-27. 10. Majumder PK, Grisanzio C, O’Connell F, Barry M, Brito JM, Xu Q, Guney I, Berger R, Herman P, Bikoff R, et al: A prostatic intraepithelial neoplasia- dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell 2008, 14(2):146-155. 11. Roy S, Kaur M, Agarwal C, Tecklenburg M, Sclafani RA, Agarwal R: p21 and p27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells. Mol Cancer Ther 2007, 6(10):2696-2707. 12. Cuadrado M, Gutierrez-Martinez P, Swat A, Nebreda AR, Fernandez- Capetillo O: p27Kip1 stabilization is essential for the maintenance of cell cycle arrest in response to DNA damage. Cancer Res 2009, 69(22):8726-8732. 13. Shaffer DR, Viale A, Ishiwata R, Leversha M, Olgac S, Manova K, Satagopan J, Scher H, Koff A: Evidence for a p27 tumor suppressive function independent of its role regulating cell proliferation in the prostate. Proc Natl Acad Sci USA 2005, 102(1):210-215. 14. Hu L, Ibrahim S, Liu C, Skaar J, Pagano M, Karpatkin S: Thrombin induces tumor cell cycle activation and spontaneous growth by down-regulation of p27Kip1, in association with the up-regulation of Skp2 and MiR-222. Cancer Res 2009, 69(8):3374-3381. 15. Di Cristofano A, De Acetis M, Koff A, Cordon-Cardo C, Pandolfi PP: Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 2001, 27(2):222-224. 16. Kwabi-Addo B, Giri D, Schmidt K, Podsypanina K, Parsons R, Greenberg N, Ittmann M: Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci USA 2001, 98(20):11563-11568. 17. Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, Khoo AS, Roy-Burman P, Greenberg NM, Van Dyke T, et al: Pten dose dictates cancer progression in the prostate. PLoS Biol 2003, 1(3):E59. 18. Besson A: [p27Kip1: tumor suppressor and oncogene?]. Med Sci (Paris) 2007, 23(12):1089-1091. Page 11 of 12 19. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ: The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 1998, 396(6707):177-180. 20. Philipp-Staheli J, Payne SR, Kemp CJ: p27(Kip1): regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exp Cell Res 2001, 264(1):148-168. 21. Vis AN, Noordzij MA, Fitoz K, Wildhagen MF, Schroder FH, van der Kwast TH: Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44 s in surgically treated patients with prostate cancer. J Urol 2000, 164(6):2156-2161. 22. Lotan R: Retinoids in cancer chemoprevention. Faseb J 1996, 10(9):1031-1039. 23. McCormick DL, Rao KV, Steele VE, Lubet RA, Kelloff GJ, Bosland MC: Chemoprevention of rat prostate carcinogenesis by 9-cis-retinoic acid. Cancer Res 1999, 59(3):521-524. 24. Christov KT, Moon RC, Lantvit DD, Boone CW, Steele VE, Lubet RA, Kelloff GJ, Pezzuto JM: 9-cis-retinoic acid but not 4-(hydroxyphenyl) retinamide inhibits prostate intraepithelial neoplasia in Noble rats. Cancer Res 2002, 62(18):5178-5182. 25. Touma SE, Perner S, Rubin MA, Nanus DM, Gudas LJ: Retinoid metabolism and ALDH1A2 (RALDH2) expression are altered in the transgenic adenocarcinoma mouse prostate model. Biochem Pharmacol 2009, 78(9):1127-1138. 26. Gudas LJ, Sporn MB, Roberts AB: Cellular biology and biochemistry of retinoids. In The Retinoids: Biology, Chemistry, and Medicine. Edited by: Sporn M, Roberts A, Goodman D. New York: Raven Press; 1994. 27. Hail N Jr, Chen P, Kepa JJ: Selective apoptosis induction by the cancer chemopreventive agent N-(4-hydroxyphenyl)retinamide is achieved by modulating mitochondrial bioenergetics in premalignant and malignant human prostate epithelial cells. Apoptosis 2009, 14(7):849-863. 28. Teixeira LT, Kiyokawa H, Peng XD, Christov KT, Frohman LA, Kineman RD: p27Kip1-deficient mice exhibit accelerated growth hormone-releasing hormone (GHRH)-induced somatotrope proliferation and adenoma formation. Oncogene 2000, 19(15):1875-1884. 29. Christov KT, Moon RC, Lantvit DD, Boone CW, Kelloff GJ, Steele VE, Lubet RA, Pezzuto JM: Prostate intraepithelial neoplasia in Noble rats, a potential intermediate endpoint for chemoprevention studies. Eur J Cancer 2004, 40(9):1404-1411. 30. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, et al: A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995, 92(20):9363-9367. 31. Shilkaitis A, Green A, Punj V, Steele V, Lubet R, Christov K: Dehydroepiandrosterone inhibits the progression phase of mammary carcinogenesis by inducing cellular senescence via a p16-dependent but p53-independent mechanism. Breast Cancer Res 2005, 7(6):R1132-1140. 32. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V, Perlmutter RM, et al: A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27 (Kip1)-deficient mice. Cell 1996, 85(5):733-744. 33. Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, Khanam D, Hayday AC, Frohman LA, Koff A: Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27 (Kip1). Cell 1996, 85(5):721-732. 34. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY: Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996, 85(5):707-720. 35. Leav I, Merk FB, Kwan PW, Ho SM: Androgen-supported estrogen- enhanced epithelial proliferation in the prostates of intact Noble rats. Prostate 1989, 15(1):23-40. 36. Neuhouser ML, Barnett MJ, Kristal AR, Ambrosone CB, King IB, Thornquist M, Goodman GG: Dietary supplement use and prostate cancer risk in the Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev 2009, 18(8):2202-2206. 37. Watters JL, Gail MH, Weinstein SJ, Virtamo J, Albanes D: Associations between alpha-tocopherol, beta-carotene, and retinol and prostate cancer survival. Cancer Res 2009, 69(9):3833-3841. 38. Chen W, Yan C, Hou J, Pu J, Ouyang J, Wen D: ATRA enhances bystander effect of suicide gene therapy in the treatment of prostate cancer. Urol Oncol 2008, 26(4):397-405.